NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Once again. NWBO has repeated reported the crossover (the second dose) was confounding the OS data.

From the NWBO SEC filing:
"Under the Protocol the primary endpoint was progression free survival, or PFS, and the secondary endpoint was overall survival, or OS. Both of these endpoints were confounded: the PFS endpoint by pseudo-progression, and the OS endpoint by the “crossover” provision in the trial design, which allowed all of the patients in the trial to cross over to DCVax-L treatment after tumor recurrence"

For the treatment arm, the patient was dosed with DCVax-L and upon recurrence, the "crossover" was the second dose of DCVax-L. That was the confounding.

Really calling NWBO liars??